<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02068170</url>
  </required_header>
  <id_info>
    <org_study_id>EV003</org_study_id>
    <nct_id>NCT02068170</nct_id>
  </id_info>
  <brief_title>Risk of QT-prolongation and Torsade de Pointes in Patients Treated With Acute Medication in a University Hospital</brief_title>
  <acronym>RISQ-PATH</acronym>
  <official_title>Risk of QT-prolongation and Torsade de Pointes in Patients Treated With Acute Medication in a University Hospital</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Katholieke Universiteit Leuven</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Agentschap voor Innovatie door Wetenschap en Technologie</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Katholieke Universiteit Leuven</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A prospective, observational study in a university hospital (UZ Leuven). Patients are
      included when they are treated with a potentional QT-prolonging drug: haloperidol for
      delirium, antibiotics (moxifloxacin, levofloxacin, azithromycin, clarithromycin,
      erythromycin, co-trimoxazole), antimycotics (ketoconazole, itraconazole, fluconazole,
      voriconazole), methadone, tacrolimus and oral oncolytics.

      An ECG is taken before the administration of the drug and 3-5 days after starting the drug to
      investigate the change in duration of the QTc-interval. Risk factors for developing
      QT-prolongation will be documented. Together with ECG2, an additional blood sample will be
      collected to measure the blood concentration of the drug.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>February 2014</start_date>
  <completion_date type="Actual">June 2015</completion_date>
  <primary_completion_date type="Actual">March 2015</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>change in QTc-interval (corrected for heart rate)</measure>
    <time_frame>before and 3-5 days after the start of a potentional QT-prolonging drug</time_frame>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">178</enrollment>
  <condition>Delirium</condition>
  <condition>QT-prolongation</condition>
  <arm_group>
    <arm_group_label>patients treated with a potentional QT-prolonging drug</arm_group_label>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Haloperidol, azi/clari/erythromycin, levo/moxifloxacin, co-trimoxazole, vori/keto/flu/itraconazole, methadone, tacrolimus, sunitinib</intervention_name>
    <arm_group_label>patients treated with a potentional QT-prolonging drug</arm_group_label>
    <other_name>haloperidol: Haldol, ATC-code: N05AD01</other_name>
    <other_name>azithromycin: Zitromax, ATC-code: J01FA10</other_name>
    <other_name>clarithromycin: Biclar, ATC-code: J01FA09</other_name>
    <other_name>erythromycin: Erytroforte, ATC-code: J01FA01</other_name>
    <other_name>levofloxacin: Tavanic, ATC-code: J01MA12</other_name>
    <other_name>moxifloxacin: Avelox, ATC-code: J01MA14</other_name>
    <other_name>co-trimoxazole: Bactrim, Eusaprim, ATC-code: J01EE01</other_name>
    <other_name>voriconazole: Vfend, ATC-code: J02AC03</other_name>
    <other_name>ketoconazole: Nizoral, ATC-code: J02AB02</other_name>
    <other_name>fluconazole: Diflucan, ATC-code: J02AC01</other_name>
    <other_name>itraconazole: Sporanox, ATC-code: J02AC02</other_name>
    <other_name>methadone: ATC-code: N07BC02</other_name>
    <other_name>tacrolimus: Prograft, Advagraft, ATC-code: L04AD02</other_name>
    <other_name>sunitinib: Sutent, ATC-code: L01XE04</other_name>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      -  1 blood sample (plasma) to measure the blood concentration of the drug

        -  1 blood sample (DNA) to store in a biobank for additional research
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Patients treated with acute potentional QT-prolonging medication. In a university hospital.
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  treatment with a potentional QT-prolonging drug of our list

          -  inpatient of UZ Leuven, admitted on one of the participating wards

        Exclusion Criteria:

          -  &lt; 18 years old

          -  DNR-code 3

          -  not possible to take an ECG before the start of haloperidol
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Eline Vandael, PhD-student</last_name>
    <role>Principal Investigator</role>
    <affiliation>Katholieke Universiteit Leuven</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>UZ Leuven</name>
      <address>
        <city>Leuven</city>
        <zip>3000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
  </location_countries>
  <verification_date>July 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 18, 2014</study_first_submitted>
  <study_first_submitted_qc>February 19, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 21, 2014</study_first_posted>
  <last_update_submitted>July 27, 2015</last_update_submitted>
  <last_update_submitted_qc>July 27, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 28, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Katholieke Universiteit Leuven</investigator_affiliation>
    <investigator_full_name>Eline Vandael</investigator_full_name>
    <investigator_title>PhD-student</investigator_title>
  </responsible_party>
  <keyword>QT-prolongation</keyword>
  <keyword>Torsade de Pointes</keyword>
  <keyword>QT-prolonging drugs</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Delirium</mesh_term>
    <mesh_term>Long QT Syndrome</mesh_term>
    <mesh_term>Torsades de Pointes</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tacrolimus</mesh_term>
    <mesh_term>Moxifloxacin</mesh_term>
    <mesh_term>Fluoroquinolones</mesh_term>
    <mesh_term>Clarithromycin</mesh_term>
    <mesh_term>Itraconazole</mesh_term>
    <mesh_term>Levofloxacin</mesh_term>
    <mesh_term>Ketoconazole</mesh_term>
    <mesh_term>Voriconazole</mesh_term>
    <mesh_term>Erythromycin</mesh_term>
    <mesh_term>Erythromycin Estolate</mesh_term>
    <mesh_term>Erythromycin Ethylsuccinate</mesh_term>
    <mesh_term>Sunitinib</mesh_term>
    <mesh_term>Erythromycin stearate</mesh_term>
    <mesh_term>Trimethoprim, Sulfamethoxazole Drug Combination</mesh_term>
    <mesh_term>Hydroxyitraconazole</mesh_term>
    <mesh_term>Norgestimate, ethinyl estradiol drug combination</mesh_term>
    <mesh_term>Methadone</mesh_term>
    <mesh_term>Haloperidol</mesh_term>
    <mesh_term>Haloperidol decanoate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

